Aspect Biosystems Ltd. is a Canadian biotechnology company developing implantable tissue therapeutics using microfluidic 3D bioprinting. Based in Vancouver, the company integrates cell biology, biomaterials, and advanced biofabrication to create functional tissues intended to replace, repair, or augment biological functions.
Aspect’s platform supports discovery, preclinical development, and scalable manufacturing of cell-based therapies for areas such as metabolic, endocrine, and other chronic diseases. The company conducts in-house R&D and process development and collaborates with industry and academic partners to advance bioprinted tissues toward clinical application.
None yet. When a new project in the record names Aspect Biosystems as owner, partner or investor, it shows here.
The partnership focuses on developing cellular therapies for diabetes, integrating technologies, and expanding manufacturing and R&D capabilities across Canada, the US, and Denmark.
